Abelzeta Inc.
10/20/2025 | Press release | Distributed by Public on 10/20/2025 06:15
AbelZeta Announces Late-Breaking Poster Presentation at ACR Convergence 2025 of First-in-Human Phase I Trial of anti-CD20/BCMA Bispecific CAR-T Therapy in Patients with[...]
ROCKVILLE, MD, October 20, 2025 - AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, today announced that clinical data from the first-in-human Phase I trial (NCT06249438) of C-CAR168 in patients with refractory autoimmune diseases will be presented as a late-breaking poster presentation at American College of Rheumatology (ACR) Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chicago, Illinois. C-CAR168 is an autologous anti-CD20/BCMA bispecific Chimeric Antigen Receptor T-cell (CAR-T) therapy designed to simultaneously target autoantibody-producing plasma cells and their B-cell precursors, aiming to achieve "immune reset".
Presentation Type: Poster
Session: Late-Breaking Posters
Display Dates: October 26-28, 2025
Presentation Date & Time: Tuesday, October 28 , 10:30 AM - 12:30 PM CT
Location: Hall F1, McCormick Place
Abstract ID: 2211304
Abstract Title: Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset and Sustained Drug Free Remission in Refractory Autoimmune Diseases
Abelzeta Inc. published this content on October 20, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 20, 2025 at 12:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]